T D Therapeuticsmission Is To Develop Its Lead Drug Product Candidatet D 959As A Potential Ae First In Classand Ae Best In Classdiseasemodifyingbreakthrough Medicinefor Thetreatment Of Alzheimer S Diseasewith Thepotential To Slowstop Or Reversethecourseof Thediseasethecompany Is Also Seeking To Maximizethetherapeutic Utility Of T D 959 And Has Initiated Preclinical Studies In Huntington S Diseasemodels
No conferences found for this company.
| Company Name | T3d Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
